Biostax Corp. financial data

Symbol
BTAX on OTC
Location
2431 Aloma Ave #124, Winter Park, FL
State of incorporation
Florida
Fiscal year end
December 31
Former names
Immune Therapeutics, Inc. (to 9/14/2023), TNI BIOTECH, INC. (to 10/30/2014)
Latest financial report
10-Q - Q2 2024 - Aug 19, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 0.31 % -92.2%
Debt-to-equity -104 % -25%
Return On Assets -1.14K % -109%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 83.7M shares +0.14%
Common Stock, Shares, Outstanding 83.7M shares +0.17%
Entity Public Float 11M USD +44.7%
Common Stock, Value, Issued 8.37K USD +0.17%
Weighted Average Number of Shares Outstanding, Basic 83.7M shares +0.5%
Weighted Average Number of Shares Outstanding, Diluted 83.7M shares +0.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 140K USD -93.4%
Operating Income (Loss) -1.21M USD +20.8%
Nonoperating Income (Expense) -1.01M USD +53.2%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -2.22M USD +39.8%
Earnings Per Share, Basic -0.03 USD/shares -101%
Earnings Per Share, Diluted -0.03 USD/shares -101%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 5.45K USD -68.7%
Assets, Current 2.1K USD -94%
Assets 5.45K USD -99.3%
Accounts Payable, Current 1.26M USD -7.65%
Accrued Liabilities, Current 418K USD +207%
Liabilities, Current 5.31M USD +37.5%
Liabilities 5.31M USD +37.5%
Retained Earnings (Accumulated Deficit) -386M USD -0.58%
Stockholders' Equity Attributable to Parent -5.3M USD -70.9%
Liabilities and Equity 5.45K USD -99.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -33.3K USD +87.5%
Net Cash Provided by (Used in) Financing Activities 5.62K USD -96.3%
Common Stock, Shares Authorized 750M shares 0%
Common Stock, Shares, Issued 83.7M shares +0.17%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -27.7K USD +76%
Deferred Tax Assets, Valuation Allowance 19.6M USD +5.96%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 19.6M USD +5.96%
Deferred Tax Assets, Operating Loss Carryforwards 19.6M USD +1.06%
Amortization of Intangible Assets 13.4K USD
Share-based Payment Arrangement, Expense 0 USD
Interest Expense 226K USD +431%